Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venglustat - Sanofi

Drug Profile

Venglustat - Sanofi

Alternative Names: Genz-682452-AA; Genz-682452-AU; GZ-402671; GZ/SAR402671; GZ/SAR402671A; Ibiglustat; SAR-402671; SAR402671A; Venglustat malate; Venglustat malate - Sanofi

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi; Sanofi Genzyme
  • Class Antiparkinsonians; Azabicyclo compounds; Carbamates; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fabry's disease; Gaucher's disease type III; GM2 gangliosidoses; Polycystic kidney disease
  • Phase II Gaucher's disease
  • Discontinued Parkinson's disease

Most Recent Events

  • 19 Feb 2024 Sanofi announces intention to submit regulatory application for Gaucher's disease (type 3) in 2026 or later (Sanofi pipeline, February 2024)
  • 18 Apr 2022 Phase-III clinical trials in Gaucher's disease type III (In children, In adults, In the elderly) in USA (PO) (NCT05222906) (EudraCT2021-005402-10)
  • 10 Feb 2022 Sanofi plans to submit regulatory applications for Fabry's disease in 2025 or later (Sanofi pipeline, February 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top